|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.62/1.10
|
企業價值
28.87M
|
資產負債 |
每股賬面淨值
4.54
|
現金流量 |
現金流量率
--
|
損益表 |
收益
431.38K
|
每股收益
0.24
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/17 00:13 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services. |